Immune checkpoint inhibitors in patients with rheumatoid arthritis and melanoma: a study using real world data
Active Grant Awarded
- Award ID
- K01AR085195
- Recipient
-
The Hospital For Special Surgery Fund, Inc. UEI LGHBJMLVD8H3
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $129,330
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 9% complete
- Place of performance
- New York, NY 10021, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Hospital For Special Surgery Fund, Inc., doing business as HSS Foundation, $129,330 on June 11, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award is a grant that funds a K01 career development project for Dr. Jannat-Khah, designed to make her an independent, R01-funded investigator. The study examines immune checkpoint inhibitor treatment in patients with autoimmune disease and cancer, specifically rheumatoid arthritis and melanoma. Its stated method uses Komodo HealthMap, a real-world data source, to investigate overall survival and hospitalization in immune checkpoint inhibitor-treated rheumatoid arthritis and non-rheumatoid arthritis melanoma patients. The period of performance ends May 31, 2031, and the place of performance is New York, NY 10021.
Description
- Abstract
- Background: this K01 proposal is designed for DR. Jannat-khah to become an independent, R01 funded, investigator focused on exploring the effect of immune checkpoint inhibitor (ICI) treatment in autoimmune disease (aid) patients with cancer. Icis are a novel and effective cancer treatment; however, some patients develop flares of their existing aid and/or immune related adverse events (IRAES) from ICI treatment. IRAES can occur in almost any part of the body and range in severity. Little is known about IRAES among patients with pre- existing autoimmune disease as these patients were excluded from clinical trials for icis. Among ICI treated rheumatoid arthritis (RA) patients, immunomodulatory treatment with glucocorticoids or disease modifying antirheumatic drugs (DMARDS) might be needed to treat RA flares and/or immune related adverse events (IRAES). Published results provide conflicting evidence that ICI treated RA cancer patients have worse overall survival (OS) and increased hospitalizations due to ICI treatment. Additionally, there is insufficient data on glucocorticoids and DMARDS treatment and their effect on OS for ICI treated RA cancer patients. Preliminary data: preliminary data by DR. Jannat-khah and her mentors, found ICI treated RA patients have no difference in OS compared to non-RA patients with metastatic non-small lung cancer (NSCLC) after adjusting for steroid use prior to ICI initiation in medicare data. After ICI initiation, she found dexamethasone confounds the association of glucocorticoid use and OS in ICI treated RA NSCLC patients. Lastly, we developed and published an algorithm to identify ICI-inflammatory arthritis (ICI-IA) for use in large real-world datasets (RWD). Methods: KOMODO healthmap (KOMODO), a RWD, will be used to investigate OS and hospitalization in ICI treated RA and non-RA melanoma patients. A target trial emulation will be performed to investigate treatment with glucocorticoids (ALONE) compared to combination treatment with glucocorticoids and methotrexate among ICI treated RA patients with melanoma. Lastly, the previously developed ICI-IA algorithm will be validated by comparing its performance in KOMODO together with a physician adjudicated registry of ICI-IA patients from hospital for special surgery. Career development: the overarching goal of this K01 is to use KOMODO, a RWD, and apply pharmacoepidemiologic methods to study ICI treated RA patients with melanoma. DR. Jannat-khah is an assistant scientist at hospital for special surgery and an assistant professor of epidemiology in medicine at weill cornell medical college. Under the mentorship of DR. Anne bass, a rheumatologist with expertise in treating ICI treated RA patients with cancer, and DR. Curtis, a rheumatologist and pharmacoepidemiologist with RWD experience; DR. Jannat-khah will perform the proposed research. Lastly, DR. Jannat-khah will participate in formal coursework to bolster her knowledge of statistical methods, pharmacoepidemiology, cancer immunology, and immunotherapy.
Quick answers
Who received award K01AR085195?
K01AR085195 was awarded to The Hospital For Special Surgery Fund, Inc. by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on June 11, 2026.
How much is award K01AR085195 worth?
$129,330 has been obligated on K01AR085195.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award